Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study

BACKGROUND: Leuprorelin acetate, a luteinizing hormone-releasing hormone agonist, is used worldwide in premenopausal women with hormone receptor-positive breast cancer. This study was conducted to assess the non-inferiority of the 6-month depot formulation, TAP-144-SR (6M) 22.5 mg to the 3-month dep...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurebayashi, Junichi, Toyama, Tatsuya, Sumino, Shuuji, Miyajima, Eri, Fujimoto, Tsukasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216102/
https://www.ncbi.nlm.nih.gov/pubmed/27017207
http://dx.doi.org/10.1007/s12282-016-0691-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216102/
https://www.ncbi.nlm.nih.gov/pubmed/27017207
http://dx.doi.org/10.1007/s12282-016-0691-6

Ejemplares similares